Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

By LabMedica International staff writers
Posted on 13 Aug 2025

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. More...

Until now, the decision was largely random, as neither works equally well for everyone. Now, new research has identified a genetic marker that can predict which medication will be most effective for each patient before therapy begins.

An international team led by the University of Münster (Münster, Germany) discovered that carriers of the HLA-A 03:01 tissue type respond significantly better to glatiramer acetate than to interferon beta. Their study analyzed more than 3,000 MS patients in a multicenter trial, with results published in eBioMedicine. This genetic information offers a clear, evidence-based criterion for personalized treatment selection.

Researchers examined T-cell receptor sequences in blood samples from 3,021 patients across several international cohorts. Specific T-cell clones were found after glatiramer acetate therapy only in patients with HLA-A*03:01 or HLA-DRB1*15:01. However, a proven clinical benefit—fewer symptoms and improved outcomes—was observed only in carriers of the HLA-A*03:01 allele, affecting about 30–35% of European MS patients.

The results were validated in five independent cohorts from the USA, France, and Germany, including the NationMS cohort. In all analyses, HLA-A*03:01 carriers on glatiramer acetate showed significantly better outcomes than those treated with interferon beta. This robust and reproducible finding confirms the biomarker’s clinical utility.

Because human leukocyte antigen (HLA) testing is already widely used in transplant medicine and drug safety, the discovery can be implemented in clinical consultations in the short term. Beyond guiding treatment decisions, the study also provides new insight into glatiramer acetate’s mechanism of action, suggesting that only a few protein fragments may drive its therapeutic effects. This could lead to optimized drug formulations in the future.

"Our study shows for the first time that a genetic marker is linked to the treatment success of an MS medication. This allows us to predict before starting therapy whether glatiramer acetate or interferon is likely to be the better choice," said Professor Nicholas Schwab, study leader.

Related Links:
University of Münster


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
Alcohol Testing Device
Dräger Alcotest 7000
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more

Industry

view channel
Image: The partnership between OGT and QIAGEN unlocks a complete sample to report workflow for SureSeq NGS panels (Photo courtesy of OGT)

Qiagen and Oxford Gene Technology Partner on Sequencing Panel Interpretation

In clinical research, next-generation sequencing (NGS) panels provide essential insights for genetic analysis, but many laboratories face challenges in transforming raw sequencing data into clinically... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.